BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives $42.60 Consensus Target Price from Brokerages
BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one […]
BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one […]
